Another example in which a drug developed for cancer can be used in a non-cancer condition is provided by CLOVES syndrome, which is caused by mutations in PIK3CA. Patients with CLOVES syndrome, which manifests as congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and scoliosis/skeletal and spinal anomalies, also have a propensity to Wilms tumors [112]. The gene discussed is PIK3CA; the disease is vascular malformation.